Integral Health Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Integral Health Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-243	Closed	-$507K	–	68
2022 Q1	$507K	Sell	243 -321	-57%	-$806K	0.13%	70
2021 Q4	$2.76M	Hold	564	–	–	0.76%	42
2021 Q3	$3.54M	Buy	564 +330	+141%	+$2.67M	1.02%	41
2021 Q2	$2.21M	Buy	234 +26	+13%	+$218K	0.61%	48
2021 Q1	$1.81M	Buy	+208	New	+$1.97M	0.52%	54

Other funds holding AVTX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Integral Health Asset Management's AVTX Position: Q2 2022 in Review

Integral Health Asset Management sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 243 shares — an estimated $507K sold.

Integral Health Asset Management first reported a position in AVTX in Q1 2021 and held it in 5 quarters. The position peaked at $3.54M in Q3 2021. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

Integral Health Asset Management reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
Integral Health Asset Management sold 243 Avalo Therapeutics shares in Q2 2022, an estimated $507K.
Integral Health Asset Management first reported a position in Avalo Therapeutics in Q1 2021 and held it in 5 quarters.
Integral Health Asset Management's Avalo Therapeutics position peaked at $3.54M in Q3 2021.
43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on Integral Health Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.